Loading...
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis
BACKGROUND: Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHuEPO use in predialysis patients which may accelerate the deterio...
Saved in:
| Published in: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley & Sons, Ltd
2016
|
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7144724/ https://ncbi.nlm.nih.gov/pubmed/26790135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD003266.pub3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|